FDA is eager to see submissions of new and improved continuous glucose monitors for hospital use, but acknowledges the complexities of determining appropriate study designs.
In a June 25 public meeting, FDA sought input from industry, academia and clinicians on study design and performance factors necessary to assess devices capable of performing real-time, continuous measurement...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?